pharmaphorum

MARCH 25, 2021

The other side of 2020 for Boehringer was the impact of the pandemic on its medicine sales, although the company managed to keep revenues in positive territory with a 3% increase to €19.57 The big revenue contributor was diabetes drug Jardiance (empagliflozin), which grew 15% to €2.48 billion ($23.11

Diabetes 98

Diabetes Hospitals 98

pharmaphorum

NOVEMBER 8, 2022

After years of preparation, Eli Lilly is on the brink of launching a fully connected and personalised diabetes management platform, underpinned by digital technologies. Tighter glucose control is known to reduce the risk of complications of diabetes like cardiovascular disease and nerve damage affecting the eyes and extremities.

Diabetes 63

Diabetes Communication 63

Drug Channels

JULY 29, 2020

In this issue: Pricing problems for diabetes treatments Controversy over Regeneron’s copay support Massachusetts concedes that coupons help some patients (but accumulators hurt) A 2020 update to my all-time favorite chart Plus, thoughtful perspectives on diversity from AmerisourceBergen CEO Steve Collis. d/b/a Drug Channels Institute.

Diabetes 52

Diabetes Biosimilars 52

Express Pharma

NOVEMBER 3, 2023

Saroglitazar Mg was launched in India in September 2013 for the treatment of diabetic dyslipidemia and hypertriglyceridemia in patients with type-2 diabetes not controlled by statins alone. It reduces co-morbidities (dyslipidemia, hypertriglyceridemia, and diabetes mellitus).

Diabetes 101

Diabetes 101

pharmaphorum

DECEMBER 21, 2020

2020’s M&A activity hasn’t quite reached the heights of last year’s, where two pharma mega-mergers – BMS’ buyout of Celegne and AbbVie’s acquisition of Allergan – accounted for almost 40% of total M&A deal values. Here we take a look at the biggest mergers and acquisitions of 2020 and what they might mean for the companies involved.

Biosimilars 126

Biosimilars Chemotherapy Immunity Immunization 126

pharmaphorum

JUNE 28, 2022

The two companies first started working together in 2020, initially focusing on Health2Sync’s home market of Taiwan, bundling the software with Sanofi’s insulin therapies at clinics across the country. The post Sanofi extends Health2Sync digital diabetes partnership to Japan appeared first on.

Diabetes 52

Diabetes Communication 52

STAT

SEPTEMBER 23, 2022

These 22 products compete in nine molecule classes across oncology, rheumatology, diabetes care, and now ophthalmology. billion in 2020 (three times higher than savings from 2019) and have the potential to increase to $133 billion by 2025. According to the most recent “U.S.

Biosimilars 224

Biosimilars Diabetes Drug Pricing 224

Express Pharma

OCTOBER 18, 2023

It must be taken once daily, under prescription, to improve glycemic control in patients with Type 2 diabetes. According to IQVIA sales data for the 12‐month period ending August 2023 (MAT August 2023), the market for oral anti‐diabetic drugs in India is estimated to be Rs 12,522 crores, with an annual growth of 6.5

Diabetes 99

Diabetes 99

pharmaphorum

SEPTEMBER 1, 2020

AZ halted DAPA-CKD in July after revealing that Farxiga (dapagliflozin) met its objective of slowing the worsening of renal function and cut the risk of death in patients with chronic kidney disease (CKD) with and without type 2 diabetes. . The post AZ trumpets Farxiga survival data in renal disease at ESC 2020 appeared first on.

Diabetes 52

Diabetes 52

pharmaphorum

JANUARY 31, 2022

Glooko has made a name for itself in digital health circles with its data management tools for diabetes patients, and has now added artificial intelligence capabilities with an agreement to acquire xbird. billion deal in 2020. The post Glooko adds AI to its digital diabetes tools with xbird takeover appeared first on.

Diabetes 52

Diabetes 52

Pharmafile

JANUARY 26, 2023

Published date: 26/01/2023 Summary: 26 January 2023 Galway, Ireland - Orbsen Therapeutics Limited (“Orbsen”), a global leader in stromal cell immunotherapies, today announces encouraging headline interim results from the EU Horizon 2020-funded NEPHSTROM clinical trial for Diabetic Kidney Disease (NEPHSTROM). read more

Diabetes 40

Diabetes 40

Amber

NOVEMBER 21, 2022

21, 2022) – Amber Specialty Pharmacy announces that it will begin dispensing TZIELD (teplizumab), an anti-CD3 monoclonal antibody, to delay Stage 3 Type 1 Diabetes (T1D) in patients ages 8 years and older with Stage 2 T1D. OMAHA, Neb.

Specialty Pharmacies 52

Specialty Pharmacies Diabetes 52

RX Note

APRIL 10, 2024

Malaysia Medication Adherence Assessment Tool (MyMAAT) The Malaysia Medication Adherence Assessment Tool (MyMAAT) was developed by a multidisciplinary team with expertise in medication adherence and health literacy for use with diabetic patients. External Links Pay up or retract?

Diabetes 52

Diabetes 52

pharmaphorum

AUGUST 24, 2020

What current topic will you be addressing in your presentation, and what would you say makes it relevant to 2020? “We 23 rd -24 th November 2020. The post Exclusive interview with ForwardVue Pharma released for Ophthalmic Drugs 2020 appeared first on. Ophthalmic Drugs Conference. OphthalmicDrugs. or call +44 (0)20 7827 6088.

Packaging 52

Packaging Diabetes 52

pharmaphorum

JANUARY 24, 2023

Eli Lilly is leaving nothing to chance when it comes to making the most of its fast-growing diabetes therapy Mounjaro – it is investing another $450 million at a facility in North Carolina that will make the drug. billion since 2020. That comparison was however made before Novo Nordisk launched a higher-strength version of its drug.

Diabetes 97

Diabetes Packaging 97

pharmaphorum

OCTOBER 26, 2020

Bayer’s blockbuster ambitions for diabetic kidney disease (DKD) drug candidate finerenone look a lot firmer with the publication of data from the phase 3 FIDELIO-DKD trial. Diabetes is the leading cause of kidney failure, and there are estimated to be almost 850 million people worldwide with chronic kidney disease (CKD).

Diabetes 98

Diabetes 98

pharmaphorum

APRIL 29, 2022

For many patients with type 2 diabetes, having to inject basal insulin every day is a burdensome fact of life, but Novo Nordisk is trying to change that. The lower injection frequency might also encourage type 2 diabetics to start insulin treatment earlier, and help stave off the damaging complications of the disease.

Diabetes 98

Diabetes 98

Pharmaceutical Technology

JANUARY 22, 2023

The company stated that the drug received Fast Track designation from the US FDA for the same indication in March 2020. Jardiance was initially approved in 2014 as a once-a-day tablet for use with diet and exercise to reduce blood sugar in type 2 diabetes adult patients.

Diabetes 105

Diabetes 105

RX Note

JUNE 23, 2023

The common cardiovascular risk factors include: Dyslipidemia Hypertension Diabetes Mellitus Smoking Overweight/obesity Dyslipidemia Dyslipidemia refers to the following lipid levels: Total cholesterol (TC) > 5.2 Patients with established CVD, CKD and diabetes fall into the very high and high risk categories.

Diabetes 52

Diabetes 52

Pharmaceutical Business Review

FEBRUARY 21, 2024

ISM-001 is a high-affinity, humanised antibody aimed at restoring blood flow in patients with diabetic vascular disease. IsomAb CEO Jackie Turnbull said: “IsomAb’s lead programme targeting VEGF-A 165 b aims to treat peripheral arterial disease in the large proportion of patients with concomitant metabolic syndrome and Type II diabetes. “We

Diabetes 59

Diabetes 59

RX Note

JUNE 10, 2023

Introduction The treatment approach for type 2 diabetes mellitus has undergo a shift from the traditional glucose-centric approach to the new cardiorenal-metabolic approach. This change emphasizes a comprehensive approach for reducing the risk of diabetes-related complications.

Diabetes 52

Diabetes Labelling Hospitals 52

RX Note

MARCH 8, 2024

2020) , non-Malay race (Chinese or Indian) was associated with an approximately four-fold increased risk, whereas the duration of metformin use of more than five years conferred a greater than two-fold increased risk for vitamin B12 deficiency. In a local study by Krishnan et al.

Diabetes 40

Diabetes 40

Express Pharma

NOVEMBER 12, 2023

In March 2022, desidustat was approved in India to treat anemia associated with chronic kidney disease (CKD), whereas saroglitazor was approved in June 2013 for diabetic dyslipidemia and hypertriglyceridemia. Moreover, saroglitazar is the world’s first drug to get approval for NASH.

Diabetes 94

Diabetes 94

pharmaphorum

NOVEMBER 15, 2021

It enrolled patients with and without type 2 diabetes and heart failure, to see whether treatment with Invokana (canagliflozin) can improve their symptoms, function and quality of life compared to placebo. billion in 2016 before the product was linked to an increased risk of lower limb amputation.

Diabetes 105

Diabetes Labelling 105

Express Pharma

APRIL 17, 2024

billion increase in the total value of partnership deals from 2020 to 2024 year-to-date (YTD), with more than $2 billion forged in Q1 2024 alone, reveals GlobalData. Biopharmaceutical companies are regaining interest in metabolic dysfunction-associated steatohepatitis (MASH) innovator drug development.

Drug Development 74

Drug Development Diabetes 74

ALiEM - Pharm Pearls

SEPTEMBER 25, 2023

66 year-old-male with a history of type 2 diabetes and hypertension presented as a transfer for rapid progression of lower extremity pain, swelling, and blue-purple discoloration of the entire limb with concern for a possible necrotizing infection. Epub 2020 Nov 25. He had no known thromboembolic risk factors. Phlebology.

Medical Schools 152

Medical Schools Diabetes 152

pharmaphorum

AUGUST 6, 2021

The pandemic contributed to another 90,000 apps being introduced in 2020 – an average of 250 per day – and this coupled with rising number and functionality of wearable devices “provides evidence of digital health’s accelerating innovation,” according to the IQVIA Institute for Human Data Science’s 2021 trends report.

Diabetes 145

Diabetes 145

European Pharmaceutical Review

JANUARY 12, 2024

This will be the case particularly for Jardiance ® , a treatment for type 2 diabetes, chronic heart failure and chronic kidney disease (CKD), according to Boehringer Ingelheim. In 2020, the company announced multi-year investments to expand the site and its production capacity. “We

Diabetes 92

Diabetes Pharmaceutical Companies Pharmaceutical Companies 92

RX Note

JUNE 13, 2023

External Links Clinical Inertia and Outpatient Medical Errors Clinical inertia, 2001 Clinical inertia is the enemy of therapeutic success in the management of diabetes and its complications: a narrative literature review, 2020

Clinic Management 52

Clinic Management Diabetes Communication 52

Board Vitals - Pharmacist

DECEMBER 29, 2022

Jen Trachtenberg (@askdrjen) on Sep 24, 2020 at 3:41pm PDT. doctor.mike) on Sep 29, 2020 at 6:54am PDT. A post shared by Suchismita (Tia) Paul, MD (@drspaulderm) on Sep 18, 2020 at 7:55am PDT. A post shared by Nii-Daako Darko, DO, MBA, FACS (@drniidarko) on Aug 17, 2020 at 5:05am PDT. Mike Varshavski, MD. doctor.mike .

Hospitals 98

Hospitals Medical Schools Inpatient Diabetes 98

European Pharmaceutical Review

NOVEMBER 20, 2023

Supporting European parenteral manufacture and supply Alongside expanding the company’s global parenteral product and device manufacturing network, the new facility will support the higher demand for Eli Lilly’s medicines, including its diabetes and obesity portfolio.

Diabetes 81

Diabetes 81

RX Note

SEPTEMBER 10, 2023

Treating the underlying cause , such as diabetic kidney disease, viral infections, cardiac or hepatic disorders, administration of nephrotoxic drugs. Treatment with SGLT-2 inhibitors and glucagon-like peptide 1 (GLP-1) receptor agonists may reduce the risk of kidney disease progression in patients with type 2 diabetes. g/kg/day (0.6-0.8

Diabetes 52

Diabetes Dosage Communication 52

PharmD Live

DECEMBER 21, 2021

In 2019 and 2020, there is a measurable difference in how televisits increased in underserved populations, specifically Medicaid, Medicare and minorities. Insulin, first introduced in 1921, 100 years later, 2021, diabetes monitoring devices are added to Medicare’s durable medical equipment list coverage. Aduhelm earns FDA approval.

Diabetes 52

Diabetes Hospitals 52

pharmaphorum

JANUARY 12, 2021

Boehringer and Eli Lilly have moved closer to a heart failure indication for their SGLT2 inhibitor Jardiance, as the FDA starts a fast-track review of the drug in its first use beyond diabetes. Farxiga won FDA approval for adults with HFrEF in May 2020, which helped to drive its third-quarter sales up by a third to $525 million.

Labelling 71

Labelling Diabetes 71

RX Note

DECEMBER 26, 2023

In diabetes, a burn on a foot, even mild, could lead to an amputation. External Links Burn injury, 2020 Mayo Clinic - Burns The Effect of Aloe Vera Clinical Trials on Prevention and Healing of Skin Wound: A Systematic Review, 2019 Vigilance is required. Initial Management Most minor burns can be treated at home.

Mayo Clinic 52

Mayo Clinic Diabetes Community Pharmacies 52

pharmaphorum

JANUARY 13, 2023

.” He added that people from low-income households and some racial and ethnic groups are disproportionately impacted by the practices, including Hispanic and Black people, who are much more likely to be diagnosed with diabetes than non-Hispanic white people – and much more likely to die as a result of complications.

Diabetes 105

Diabetes Drug Pricing Biosimilars 105

pharmaphorum

MARCH 2, 2022

Novo Nordisk has made its smart insulin pens available in the UK, giving people treated within the NHS for diabetes access to devices that can monitor and record dosing information for the first time. billion in 2020 to more than $16 billion by 2030, according to GlobalData.

Diabetes 52

Diabetes Communication 52